Puma Biotechnology, Inc. (PBYI)
NASDAQ: PBYI · Real-Time Price · USD
3.040
+0.130 (4.47%)
At close: May 12, 2025, 4:00 PM
3.040
0.00 (0.00%)
After-hours: May 12, 2025, 4:05 PM EDT
Puma Biotechnology Revenue
Puma Biotechnology had revenue of $46.01M in the quarter ending March 31, 2025, with 5.12% growth. This brings the company's revenue in the last twelve months to $232.71M, up 2.68% year-over-year. In the year 2024, Puma Biotechnology had annual revenue of $230.47M, down -2.19%.
Revenue (ttm)
$232.71M
Revenue Growth
+2.68%
P/S Ratio
0.64
Revenue / Employee
$1,352,959
Employees
172
Market Cap
150.90M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 230.47M | -5.17M | -2.19% |
Dec 31, 2023 | 235.64M | 7.61M | 3.34% |
Dec 31, 2022 | 228.03M | -25.12M | -9.92% |
Dec 31, 2021 | 253.16M | 28.05M | 12.46% |
Dec 31, 2020 | 225.11M | -47.15M | -17.32% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PBYI News
- 3 days ago - Puma Biotechnology, Inc. (PBYI) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Puma Biotechnology Reports First Quarter Financial Results - Business Wire
- 6 days ago - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 12 days ago - Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients - GlobeNewsWire
- 14 days ago - Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 - Business Wire
- 18 days ago - Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results - Business Wire
- 6 weeks ago - Puma SE: Undervalued With Tailwinds Ahead - Seeking Alpha
- 6 weeks ago - Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025 - Business Wire